India’s 2025 Coldrif Cough Syrup Tragedy: How a Pediatric Medicine Crisis Unfolded Across States
In late 2025, India faced one of its most serious domestic medicine safety crises in recent memory when a wave of cough syrup–related poisonings led to the deaths of dozens of young children. The outbreak, which unfolded primarily in Madhya Pradesh and Rajasthan, exposed deep vulnerabilities in drug manufacturing oversight, prescribing practices, and regulatory enforcement particularly for medicines intended for children.
At the center of the crisis was Coldrif, a commonly available cough syrup manufactured by Sresan Pharmaceuticals, which was later found to contain dangerously high levels of a toxic industrial solvent.
A Troubling Pattern Emerges
Health authorities first became alarmed in early October 2025 when hospitals in the Chhindwara district of Madhya Pradesh reported an unusual cluster of pediatric patients. Infants and toddlers who had been treated for mild respiratory symptoms rapidly deteriorated, developing severe dehydration and acute kidney injury.
Within days, multiple fatalities were recorded. By mid-October, officials confirmed that dozens of children under the age of five had died after consuming cough syrup obtained from local sources. Clinical patterns pointed not to infection, but to toxic exposure.
Laboratory testing soon identified the cause: Coldrif syrup contained extremely high concentrations of diethylene glycol (DEG), a chemical used in industrial solvents and antifreeze, and strictly prohibited in pharmaceutical formulations.
Madhya Pradesh: Coldrif at the Epicenter
State investigations in Madhya Pradesh traced all confirmed cases to Coldrif syrup produced by Sresan Pharmaceuticals at its facility in Tamil Nadu. Tests revealed that the syrup contained approximately 48.6% diethylene glycol, a concentration capable of causing rapid organ failure.
Following these findings, the Madhya Pradesh government imposed an immediate ban on Coldrif in early October. Despite this, the death toll continued to rise as previously distributed stock remained in circulation. By October 15, authorities confirmed 24 child deaths linked to the contaminated syrup, with several more children hospitalized.
Symptoms reported in affected children included persistent vomiting, abdominal pain, and a sudden inability to urinate—classic indicators of acute renal toxicity.
Rajasthan: A Separate but Parallel Crisis
Around the same time, a separate incident unfolded in Rajasthan, where three children aged between two and five died in the districts of Sikar and Bharatpur. These cases involved a government-distributed cough syrup containing the active ingredient dextromethorphan hydrobromide, manufactured by Kayson Pharma.
Unlike the Coldrif cases, laboratory tests did not confirm the presence of diethylene glycol in this syrup. However, authorities suspected improper dosing, contamination, or unsafe administration, particularly given the young age of the children.
As a precaution, the Rajasthan government immediately suspended the distribution of all Kayson Pharma medicines under its free drug scheme and halted the use of dextromethorphan-based syrups for children.
Other Contaminated Products Identified
Further testing uncovered two additional syrups—Respifresh TR and ReLife, manufactured in Gujarat—that also tested positive for diethylene glycol. While these products were not directly linked to reported deaths, their contamination reinforced concerns that the problem extended beyond a single manufacturer.
Regulators ordered recalls of these products and suspended manufacturing operations at the respective facilities.
National Investigation and WHO Intervention
As the scale of the crisis became clear, Indian health authorities launched a coordinated national investigation. The Central Drugs Standard Control Organisation (CDSCO), in collaboration with institutions such as Indian Council of Medical Research, AIIMS Nagpur, and NEERI, began analyzing clinical data and drug samples from multiple states.
Testing confirmed that contamination was batch-specific, not widespread across the retail market—suggesting manufacturing failures rather than systemic adulteration at the pharmacy level.
On 8 October, Indian authorities formally notified the World Health Organization, which issued a global Medical Product Alert days later. The alert warned healthcare providers worldwide about specific contaminated batches of Coldrif, Respifresh TR, and ReLife, and urged countries to block their use, especially in children.
Criminal Charges and Arrests
Law-enforcement agencies filed criminal cases under the Drugs and Cosmetics Act and other sections of the penal code. G. Ranganathan, the owner of Sresan Pharmaceuticals, was named in a manslaughter case and arrested.
Investigators also arrested a prescribing doctor in Madhya Pradesh for negligent medical practice, citing improper prescribing of cough syrup to infants. Charge sheets referenced serious offences, including drug adulteration and culpable homicide not amounting to murder.
Financial investigations were also launched, with enforcement agencies examining potential irregularities linked to procurement and manufacturing.
Government Crackdown and Policy Changes
In response to the crisis, the Tamil Nadu government cancelled all manufacturing licences of Sresan Pharmaceuticals, sealed its facility, and enforced a nationwide ban on Coldrif syrup.
Other states followed with recalls, production suspensions, and audits of pediatric medicines. Rajasthan suspended senior drug-control officials and appointed expert committees to review procurement and prescribing protocols.
National health authorities reissued guidelines advising that:
Cough and cold medicines should not be used in children under two years
Syrups should be prescribed cautiously for children under five
Clear warning labels must be displayed on pediatric formulations
Doctors must strictly adhere to dosing guidelines
Conclusion
India’s 2025 cough syrup tragedy was not a single failure, but a cascade of breakdowns—from manufacturing lapses and regulatory blind spots to unsafe prescribing practices. The deaths of young children transformed a routine medicine into a national emergency, forcing regulators, doctors, and manufacturers to confront long-standing weaknesses in drug safety systems.
While swift action has since removed contaminated products from circulation, the episode underscores a hard truth: when medicine safety fails, the cost is measured in lives. Sustained reforms, vigilant enforcement, and heightened public awareness will be essential to prevent such tragedies from recurring.